Ultrasound-assisted Carbon Nanoparticle Suspensions Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy in Patients With Early Breast Cancer (UltraCars): a Prospective, Randomized Controlled Phase 3 Trial
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 330
- 试验地点
- 1
- 主要终点
- The identification rate of SLNs
研究概览
简要总结
The investigators suggested ultrasound-assisted Carbon nanoparticle suspensions (CNSs) mapping had great clinical value in clinical application and might serve as a useful alternative to the dual-tracer-guided SLNB. The investigators designed this prospective, randomized controlled phase 3 trial, to compare the feasibility and diagnostic performance of ultrasound-assisted carbon nanoparticle suspensions mapping versus dual-tracer-guided sentinel lymph node biopsy in patients with early breast cancer.
详细描述
The study was a single-center, open-label, randomized controlled, non-inferiority, phase 3 trial. Eligible participants were 18 year's of age or older and had histologically confirmed primary invasive breast cancer, or ductal carcinoma in situ scheduled for mastectomy, without clinical or radiological nodal involvement (cN0) or with clinical positive lymph nodes (cN1) that were downstaged to cN0 following neoadjuvant chemotherapy (NCT); and had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Participants were randomly assigned (1:1) using a permuted block randomization scheme to receive either ultrasound-assisted CNSs (UC group) or CNSs plus ICG dual-tracer-guided (GC group) SLN mapping.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The participants must be female and 18 years of age or older.
- •Resectable invasive adenocarcinoma of the breast, confirmed histologically.
- •Ductal carcinoma in situ confirmed histologically.
- •The participants must be a preoperative clinical Tis, T1, T2, T3 as well as clinical M0 breast cancer.
- •Without clinical or radiological nodal involvement (cN0): No positive ipsilateral axillary lymph nodes; No prior removal of ipsilateral axillary lymph nodes; No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven nonmalignant by biopsy.
- •With clinical positive lymph nodes (cN1) (including any abnormal or enlarged clinically palpable lymph nodes or core biopsy/surgical biopsy/FNA evidence of malignant cell within any lymph nodes) that was downstaged to cN0 following neoadjuvant therapy.
- •The participants must have an ECOG performance status of Grade 0-
- •The participants must provide written informed consent before participating in the study.
排除标准
- •The breast has ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude. Tethering or dimpling of the skin or nipple inversion allowed.
- •The participants has a known hypersensitivity to tracers planned for use during SLNB.
- •Other prior breast malignancy except lobular carcinoma in situ.
- •The participants has had prior breast implants.
- •The participants has had prior breast reduction surgery.
- •The participants has had other prior surgery in the upper, outer quadrant, areola, or axilla to the indicated breast.
- •The participants has a positive pregnancy test or is lactating.
- •The participants has participated in another investigational drug study during the 30 days prior to signing informed consent.
研究组 & 干预措施
UC group
Ultrasound-assisted CNSs guided SLN mapping
干预措施: UC group: ultrasound-assisted CNSs guided (Procedure)
GC group
CNSs plus ICG dual-tracer-guided SLN mapping
干预措施: GC group: CNSs plus ICG dual-tracer-guided (Procedure)
结局指标
主要结局
The identification rate of SLNs
时间窗: within 14 days of SLNB
Defined as the number of patients who at least one SLN were detected divided by the total number of patients included.
次要结局
- The mean number of SLNs collected(within 14 days of SLNB)
- Operative time(within 14 days of SLNB)
- Intraoperative or postoperative complications(within 30 days of SLNB)
研究者
Kun Wang
Professor
Guangdong Provincial People's Hospital